Rezolute Investor Relations Material
Latest events
AGM 2024
Rezolute
Q3 2025
13 May, 2025
Q2 2025
12 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Rezolute Inc
Access all reports
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases, particularly those related to chronic glucose imbalances. The company's lead product, RZ358, is a human monoclonal antibody currently in clinical trials aimed at treating congenital hyperinsulinism, a rare pediatric disorder. Additionally, Rezolute is working on RZ402, an oral plasma kallikrein inhibitor, intended for the treatment of diabetic macular edema. The company is headquartered in Redwood City, California, and its shares are listed on the NASDAQ.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
RZLT
Country
🇺🇸 United States